patients—a Dutch colorectal cancer group study . J Clin Oncol 2005 ; 23 : 6199 – 6206 . 94 Tepper JE O’Connell M Niedzwiecki D . Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114 . J
Search Results
Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett
Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani
are perhaps most intriguing, 61 which randomized 1059 patients with stage II or III gastric cancer who underwent D2 surgical resection to either observation or 1 year of oral S-1 adjuvant therapy. S-1 is an orally active combination of tegafur (i
Stanley J. Miller, Murad Alam, James Andersen, Daniel Berg, Christopher K. Bichakjian, Glen Bowen, Richard T. Cheney, L. Frank Glass, Roy C. Grekin, Dennis E. Hallahan, Anne Kessinger, Nancy Y. Lee, Nanette Liegeois, Daniel D. Lydiatt, Jeff Michalski, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Thomas Olencki, Allan R. Oseroff, Clifford S. Perlis, E. William Rosenberg, Ashok R. Shaha, Marshall M. Urist, and Linda C. Wang
survival in early-stage disease—results from a review of 82 consecutive cases diagnosed between 1992 and 2004 . Ann Surg Oncol 2007 ; 14 : 1943 – 1952 . 39 Garneski KM Nghiem P . Merkel cell carcinoma adjuvant therapy: current data support
the latest updates to the Pancreatic Guideline and provided his perspective regarding adjuvant therapy in pancreatic disease. NCCN Breast Cancer Panel Chair Dr. Robert Carlson provided the NCCN Guidelines for Breast Cancer update and an insightful
Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy
excision and no adjuvant therapy . J Gastrointest Surg 1999 ; 3 : 642 – 647 . 16 Guillem JG Diaz-Gonzalez JA Minsky BD . cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted . J Clin Oncol 2008 ; 26
Al B. Benson III, Michael I. D’Angelica, Thomas A. Abrams, Chandrakanth Are, P. Mark Bloomston, Daniel T. Chang, Bryan M. Clary, Anne M. Covey, William D. Ensminger, Renuka Iyer, R. Kate Kelley, David Linehan, Mokenge P. Malafa, Steven G. Meranze, James O. Park, Timothy Pawlik, James A. Posey, Courtney Scaife, Tracey Schefter, Elin R. Sigurdson, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Yun Yen, Andrew X. Zhu, Karin G. Hoffmann, Nicole R. McMillian, and Hema Sundar
Cancers Local recurrence after surgery is a primary limitation for cure in patients with biliary tract cancers, which provides an important justification for the use of adjuvant therapy. Nevertheless, the role of adjuvant chemotherapy or chemoradiation
Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin
guidelines, visit NCCN.org . 2. Macdonald OK Crane CH . Palliative and postoperative radiotherapy in biliary tract cancer . Surg Oncol Clin N Am 2002 ; 11 : 941 – 954 . 3. Hoehn RS Wima K Ertel AE . Adjuvant therapy for
Julia T. van Groningen, Pieter van Hagen, Rob A.E.M. Tollenaar, Jurriaan B. Tuynman, Perla J. Marang-van de Mheen, Pascal G. Doornebosch, Pieter J. Tanis, Eelco J.R. de Graaf, and on behalf of the Dutch Colorectal Audit
evidence. 16 Long-term outcomes of both neoadjuvant and adjuvant therapy and local excision need to be confirmed by large prospective randomized trials. Currently, the Dutch national guidelines consider these treatments experimental and state that these
Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst
adjuvant treatment to improve outcomes, and several trials have evaluated escalation of adjuvant therapy. 16 – 18 The recently published CREATE-X trial 19 evaluated 910 patients with HER2-negative breast cancer who had residual invasive disease or LN
Natasha Satkunam, Xuejiao Wei, James J. Biagi, Sulaiman Nanji, and Christopher M. Booth
. References 1. NIH consensus conference . Adjuvant therapy for patients with colon and rectal cancer . JAMA 1990 ; 264 : 1444 – 1450 . 2. IMPACT Investigators . Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
